About Us


Sheila Oren

Dr. Oren received her MD degree and an MBA from Tel Aviv University and IDC, Israel. She was Chief Medical Officer at NeuroDerm, a clinical-stage pharmaceutical company developing drug-device combination treatments for CNS disorders (since 2008), where she lead product strategy, clinical development and regulatory affairs. Dr. Oren teamed for the IPO of NeuroDerm on Nasdaq in November 2014, which was later acquired by Mitsubishi Tanabe Pharma Corporation (MTPC) for US$1.1 Billion. Her prior experience (16 years with Teva Pharmaceutical Industries) covered the clinical development and medico-marketing plans and executions for new CNS drugs globally. Specifically, she was central in the development, approval, and launch of rasagiline (Azilect). She was also key in the design of rasagiline neuroprotection study for Parkinson’s disease (the ADAGIO delayed-start study), published in the New England Journal of Medicine in 2009.

Irit Zalayet
CPA, M.A. in Law - CFO

Ms. Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar- Ilan University. Ms. Zalayet also serves as the CFO of Stem Cell Medicine.

Cheryl Fitzer-Attas
PhD, MBA - Head of Medical Affairs

Dr. Cheryl Fitzer-Attas has >20 years of experience in the life sciences industry, with a clinical focus on neurological indications. Today, Cheryl is President of ClinMed LLC, where she works with several companies as Senior Advisor for clinical and medical affairs. Previously, Cheryl was Senior Medical Director at Mitsubishi Tanabe Pharma America, where she established the US and global medical affairs roadmaps for a new drug-device treatment for Parkinson’s disease. Before that, Cheryl was Vice President Clinical Research at CHDI, a not-for-profit research organization dedicated to acceleration of treatments for Huntington’s disease. Previously, at Teva Pharmaceuticals Industries, Cheryl was Global Medical Director for the Parkinson’s disease drug Azilect, where she played a pivotal role in the scientific communication of Azilect’s clinical trial data, including presentation and moderation at a public FDA Advisory Committee meeting. Dr. Fitzer-Attas has a B.Sc. in biology from the Hebrew University of Jerusalem, a Ph.D. in cell biology from the Weizmann Institute of Science, an MBA in marketing from Reichmann University, and she completed post-doctoral trainings at both the Weizmann Institute of Science and the University of California, San Francisco.

Dan Teleman
MSc, MBA - President

Dan Teleman is an Executive Partner at Israel Biotech Fund where he works closely with portfolio companies. Dan is currently the Chairman of Tamarix Pharma, an early stage ophthalmology company developing novel anti apoptotic molecules. Dan brings over 20 years of experience in the biotechnology industry. Dan was recently the CEO of Atox Bio, where he led the company through an NDA submission for Reltecimod, the first immunomodulator developed for NSTI. Previously, Dan was the co-founder and CEO of PainReform (Nasdaq: PRFX), head of business development for Pharmos (Nasdaq: PARS) and held marketing and sales roles at Amgen. Dan is experienced in company formation, growth and fund raising. Dan holds an MBA from Duke University, Fuqua School of Business, and an MSc in Biochemical engineering from the Ben Gurion University.

Hadas Friedman
MSc - VP QA, RA & Clinical Affairs

Ms. Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this Ms. Friedman served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Hadas has completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.

Danny Fishelovitch
PhD - Head of CMC

Dr. Danny Fishelovitch has over 15 years of experience in the pharmaceutical industry. He Headed the Chemistry, Manufacturing and Controls (CMC) at several Biotech companies including Enlivex Therapeutics, Mitoconix Bio and Neuroderm that was acquired by Mitsubishi Tanabe Pharma group. Prior to that, Danny was a CMC leader and a lead formulator at Teva pharmaceuticals Ltd. Innovative R&D. Danny had also founded DFarma consulting and provides CMC consulting services for Biopharma companies. Danny specializes in the development of various sterile and solid dosage forms as well as drug device combination dealing with small molecules, Biopharmaceuticals such as peptides and proteins and cell based advanced therapeutic medicinal products (ATMPs). In addition, Danny has extensive experience in the development, scale-up and optimization of manufacturing processes by applying Quality-by-Design methodology. Danny was involved in clinical development plans (early POC to late-stage phase III) and in marketing regulatory applications. Danny is a pharmacist and computer scientist by training and holds a Ph.D. in Structural Biology from the Tel-Aviv University. He is an author of eight published scientific papers.

Irit Aish

Ms. Aish brings over 25 years of experience in the pharmaceutical industry leading global marketing strategies of global brands, launching new products, evaluating and developing solid business plans to enrich companies’ pipeline through 505b(2). Prior to joining Pharma2B, Irit led the global marketing of Parkinson disease at Teva Pharmaceuticals. Beforehand, she held various international positions in the CNS therapeutic area. Irit holds a Bachelors of Science from Tel-Aviv University and an Executive MBA from Boston University.

Pninit Litman
PhD - VP Clinical & Pharmacology

Dr. Litman, serves as Pharma Two B's head of pharmacology and clinical studies since 2008. Prior to this Dr. Litman served as head of biology at Develogen Israel LTD and Peptor LTD where she gained extensive experience in investigational new drug development. Dr. Litman received her B.Sc. in microbiology from the Hebrew University of Jerusalem , Ph.D. in neurobiology from Weizmann Institute of Science and completed her post-doctoral training at Stanford University Medical Center, in USA.

Thank you!

An email was sent with access to our exclusive materials.
Please check your inbox and spam folder.

Please subscribe for this

Get this exclusive content straight to your email